NASDAQ:IVA Inventiva (IVA) Stock Price, News & Analysis $3.30 -0.07 (-1.93%) Closing price 03:55 PM EasternExtended Trading$3.25 -0.04 (-1.37%) As of 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Inventiva Stock (NASDAQ:IVA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Inventiva alerts:Sign Up Key Stats Today's Range$3.16▼$3.4950-Day Range$2.75▼$3.8952-Week Range$1.53▼$4.05Volume7,932 shsAverage Volume63,208 shsMarket Capitalization$315.21 millionP/E RatioN/ADividend YieldN/APrice Target$10.40Consensus RatingModerate Buy Company OverviewInventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.Read More… Inventiva Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks43rd Percentile Overall ScoreIVA MarketRank™: Inventiva scored higher than 43% of companies evaluated by MarketBeat, and ranked 717th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingInventiva has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageInventiva has only been the subject of 2 research reports in the past 90 days.Read more about Inventiva's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Inventiva are expected to grow in the coming year, from ($2.08) to ($1.85) per share. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.97% of the float of Inventiva has been sold short.Short Interest Ratio / Days to CoverInventiva has a short interest ratio ("days to cover") of 22, which indicates bearish sentiment.Change versus previous monthShort interest in Inventiva has recently decreased by 12.14%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInventiva does not currently pay a dividend.Dividend GrowthInventiva does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.97% of the float of Inventiva has been sold short.Short Interest Ratio / Days to CoverInventiva has a short interest ratio ("days to cover") of 22, which indicates bearish sentiment.Change versus previous monthShort interest in Inventiva has recently decreased by 12.14%, indicating that investor sentiment is improving significantly. News and Social Media1.9 / 5News Sentiment0.36 News SentimentInventiva has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Inventiva this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for IVA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Inventiva insiders have not sold or bought any company stock.Percentage Held by Insiders32.00% of the stock of Inventiva is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 19.06% of the stock of Inventiva is held by institutions.Read more about Inventiva's insider trading history. Receive IVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Inventiva and its competitors with MarketBeat's FREE daily newsletter. Email Address IVA Stock News HeadlinesINVENTIVA: Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech ConferenceMay 27 at 4:27 PM | finanznachrichten.deInventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech ConferenceMay 27 at 4:00 PM | globenewswire.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 28, 2025 | Porter & Company (Ad)Inventiva S.A. reports Q1 resultsMay 23, 2025 | seekingalpha.comINVENTIVA: Inventiva reports 2025 First Quarter Financial InformationMay 23, 2025 | finanznachrichten.deInventiva reports 2025 First Quarter Financial Information¹May 23, 2025 | globenewswire.comResults of the Votes of the Combined Shareholders' General Meeting of May 22, 2025May 23, 2025 | globenewswire.comDescription of the Share Repurchase Program Covered by the Liquidity Agreement with Kepler ChevreuxMay 22, 2025 | uk.finance.yahoo.comSee More Headlines IVA Stock Analysis - Frequently Asked Questions How have IVA shares performed this year? Inventiva's stock was trading at $2.14 on January 1st, 2025. Since then, IVA shares have increased by 54.0% and is now trading at $3.2950. View the best growth stocks for 2025 here. When did Inventiva IPO? Inventiva (IVA) raised $103 million in an IPO on Friday, July 10th 2020. The company issued 7,500,000 shares at a price of $13.68 per share. Jefferies, Stifel and Guggenheim Securities acted as the underwriters for the IPO and H.C. Wainwright, Roth Capital Partners and KBC Securities were co-managers. Who are Inventiva's major shareholders? Inventiva's top institutional investors include Wealth Enhancement Advisory Services LLC (0.02%). How do I buy shares of Inventiva? Shares of IVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Inventiva own? Based on aggregate information from My MarketBeat watchlists, some other companies that Inventiva investors own include Kinross Gold (KGC), Outlook Therapeutics (OTLK), Accuray (ARAY), Carnival Co. & (CCL), Alibaba Group (BABA), PayPal (PYPL). Company Calendar Today5/28/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IVA CIK1756594 Webwww.inventivapharma.com Phone33-3-80-44-75-00FaxN/AEmployees100Year Founded2011Price Target and Rating Average Stock Price Target$10.40 High Stock Price Target$17.00 Low Stock Price Target$3.00 Potential Upside/Downside+215.6%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.59 Quick Ratio0.59 Sales & Book Value Annual Sales$9.20 million Price / Sales34.27 Cash FlowN/A Price / Cash FlowN/A Book Value($0.67) per share Price / Book-4.92Miscellaneous Outstanding Shares95,662,000Free Float35,684,000Market Cap$315.21 million OptionableNot Optionable Beta0.80 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:IVA) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored“You all just got a lot richer”Trump Knows What He’s Doing. When the president says he’s going to let RFK “go wild” … and Big Pharma crash...Brownstone Research | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inventiva S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inventiva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.